Radiopharmaceutical therapy in the era of precision medicine

European Journal of Cancer

Volumn 50, Issue 13, 2014, Pages 2360-2363

  Sgouros, George ^a   Goldenberg, David M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Dosimetry; Patient specific radionuclide therapy; Radiopharmaceutical therapy; Treatment planning

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

HUMAN; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; RADIATION DOSE; RADIOMETRY;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE;

EID: 84905125364     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.025     Document Type: Article

References (30)

1. G. Iyer, A.J. Hanrahan, and M.I. Milowsky et al. Genome sequencing identifies a basis for everolimus sensitivity Science. 338 6104 2012 221
2. H.L. McLeod Cancer pharmacogenomics: early promise, but concerted effort needed Science 339 6127 2013 1563 1566
3. J. Hansen, and R. Iyengar Computation as the mechanistic bridge between precision medicine and systems therapeutics Clin Pharmacol Ther 93 1 2012 117 128
4. Committee on a framework for development of a new taxonomy of disease Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease 2011 National Academy of Sciences Washington, DC
5. J.T. Garrett, and C.L. Arteaga Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications Cancer Biol Ther 11 9 2011 793 800
6. T. Skorski Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state Leuk Lymphoma 52 S1 2011 23 29
7. M.E. Gorre, M. Mohammed, and K. Ellwood et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 5531 2001 876 880
8. J. Downward Targeting RAF: trials and tribulations Nat Med 17 3 2011 286 288
9. M. Pàez-Ribes, E. Allen, and J. Hudock et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 3 2009 220 231
10. J.M.L. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 3 2009 232 239
11. P.J. Stephens, P.S. Tarpey, and H. Davies et al. The landscape of cancer genes and mutational processes in breast cancer Nature 486 7403 2012 400 404
12. A.L. Ho, R.K. Grewal, and R. Leboeuf et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer N Engl J Med 368 7 2013 623 632
13. M.S. Kaminski, M. Tuck, and J. Estes et al. I-131-tositumomab therapy as initial treatment for follicular lymphoma N Engl J Med 352 5 2005 441 449
14. F. Morschhauser, J. Radford, and A. Van Hoof et al. Phase III trial of consolidation therapy with yttrium-90 ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 32 2008 5156 5164
15. A.J. Ocean, K.L. Pennington, and M.J. Guarino et al. Fractionated radioimmunotherapy with Y-90-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer Cancer 118 22 2012 5497 5506
16. V. Ambrosini, M. Fani, S. Fanti, F. Forrer, and H.R. Maecke Radiopeptide imaging and therapy in Europe J Nucl Med. 52 Suppl 2 2011 42S 55S
17. J.C. Sisson, and G.A. Yanik Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors Semin Nucl Med 42 3 2012 171 184
18. S.A. Hundahl, I.D. Fleming, A.M. Fremgen, and H.R. Menck A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 Cancer 83 12 1998 2638 2648
19. A.G. Bell The uses of radium Am Med 6 1903 261
20. J.G. Jurcic, S.M. Larson, and G. Sgouros et al. Targeted alpha-particle immunotherapy for myeloid leukemia Blood 100 4 2002 1233 1239
21. C. Parker, S. Nilsson, and D. Heinrich et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 3 2013 213 223
22. T.L. Rosenblat, M.R. McDevitt, and D.A. Mulford et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia Clin Cancer Res 16 21 2010 5303 5311
23. E. Basch Toward patient-centered drug development in oncology N Engl J Med 2013
24. D.M. Goldenberg, F. DeLand, and E. Kim et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning N Engl J Med 298 25 1978 1384 1386
25. S.M. Larson, J.A. Carrasquillo, and K.A. Krohn et al. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy J Clin Investig 72 6 1983 2101 2114
26. P. Holliger, and P.J. Hudson Engineered antibody fragments and the rise of single domains Nat Biotechnol 23 9 2005 1126 1136
27. H. Song, and G. Sgouros Radioimmunotherapy of solid tumors: searching for the right target Curr Drug Deliv 8 1 2011 26 44
28. W.J. McBride, P. Zanzonico, and R.M. Sharkey et al. Bispecific antibody pretargeting PET (ImmunoPET) with an I-124-labeled hapten-peptide J Nucl Med 47 10 2006 1678 1688
29. G. Sgouros, E. Frey, R. Wahl, B. He, A. Prideaux, and R. Hobbs Three-dimensional imaging-based radiobiological dosimetry Semin Nucl Med 38 5 2008 321 334
30. G. Sgouros, J.C. Roeske, and M.R. McDevitt et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy J Nucl Med 51 2 2010 311 328